Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Error in Table 2

Error in Table 2 Letters to recurrence—this is seen in the curves in Figure 3 (the low- CORRECTION risk curves are flat and the high-risk curves are peaked). Errors in Table: In the Original Investigation by Yoshino et al titled “Efficacy and We propose that the annual risk of reactivation is attenu- Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin- Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 ated by tamoxifen. In the high-risk group, use of tamoxifen de- Randomized Clinical Trial,” published online September 12, 2019, and printed lays the reactivation of cancers, but at the end of active treat- November 14, 2019, a column head in Table 2 was misspelled. The correct ment, more residual dormant cancers are present in the spelling is mFOLFOX6. There was also a data error in Table 2. This article was metastatic niche than in the untreated group. We predict that corrected online. This article was also corrected on November 14, 2019, to change to CC-BY-NC-ND open access status. after tamoxifen cessation, the dormant cancers will slowly 1. Yoshino T, Yamanaka T, Oki E, et al. Efficacy and long-term peripheral emerge from quiescence, and we will observe a switch from sensory http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Error in Table 2

JAMA Oncology , Volume 6 (2) – Feb 1, 2020

Error in Table 2

Abstract

Letters to recurrence—this is seen in the curves in Figure 3 (the low- CORRECTION risk curves are flat and the high-risk curves are peaked). Errors in Table: In the Original Investigation by Yoshino et al titled “Efficacy and We propose that the annual risk of reactivation is attenu- Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin- Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 ated by tamoxifen. In the high-risk group, use of tamoxifen...
Loading next page...
 
/lp/american-medical-association/error-in-table-2-4IdAPkXM3h
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.6921
Publisher site
See Article on Publisher Site

Abstract

Letters to recurrence—this is seen in the curves in Figure 3 (the low- CORRECTION risk curves are flat and the high-risk curves are peaked). Errors in Table: In the Original Investigation by Yoshino et al titled “Efficacy and We propose that the annual risk of reactivation is attenu- Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin- Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 ated by tamoxifen. In the high-risk group, use of tamoxifen de- Randomized Clinical Trial,” published online September 12, 2019, and printed lays the reactivation of cancers, but at the end of active treat- November 14, 2019, a column head in Table 2 was misspelled. The correct ment, more residual dormant cancers are present in the spelling is mFOLFOX6. There was also a data error in Table 2. This article was metastatic niche than in the untreated group. We predict that corrected online. This article was also corrected on November 14, 2019, to change to CC-BY-NC-ND open access status. after tamoxifen cessation, the dormant cancers will slowly 1. Yoshino T, Yamanaka T, Oki E, et al. Efficacy and long-term peripheral emerge from quiescence, and we will observe a switch from sensory

Journal

JAMA OncologyAmerican Medical Association

Published: Feb 1, 2020

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month